Previous 10 | Next 10 |
iBio, Inc. (IBIO) Q2 2021 Earnings Conference Call February 16, 2021 04:30 PM ET Company Participants Stephen Kilmer - Investor Relations Tom Isett - Chairman & Chief Executive Officer John Delta - Principal Accounting Officer Conference Call Participants Kristen Kluska - Cantor Fitzgeral...
For fiscal Q2 2021, iBio (IBIO)'s revenue was slightly above analyst expectations.Total operating expenses more than doubled from the year ago period from $3.5M to $8.3M.R&D expenses went from $0.9M to $2.4M over the period.Net loss narrowed over the period to $8.2M (4 cents per shar...
iBio (IBIO): FQ2 GAAP EPS of -$0.04.Revenue of $0.71M (+129.0% Y/Y) beats by $0.06M.As of December 31, 2020, iBio had cash and cash equivalents plus investments in debt securities of approximately $107.6 million.Press Release For further details see: iBio beats on revenue
BRYAN, Tx., Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended December 31, 2020. ...
BRYAN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Robert M. Lutz as its Chief Financial & Business O...
U.K. residents could have to present a so-called COVID-19 vaccine passport to get into bars and grocery stores in the future, according to Foreign Secretary Dominic Raab."It's something that hasn’t been ruled out and it's under consideration, but of course you've got to make it workabl...
BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 second quarter financial results afte...
Palm Beach, FL – January 25, 2021 Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been r...
Shares of iBio (NYSEMKT: IBIO) surged on Friday following positive analyst commentary. As of 1:35 p.m. EDT, the biologics manufacturer's stock was up more than 14%. Cantor Fitzgerald analyst Kristen Kluska placed an overweight rating on iBio's stock after the market close on Thu...
iBio (IBIO) has risen more than fourfold in value over the past six-month period amid COVID-19 vaccine hopes. That has not discouraged Cantor Fitzgerald to initiate the stock’s coverage with an overweight rating with a price target of $3, more than double the previous close. The shares...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...